Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.

Posavi M, Diaz-Ortiz M, Liu B, Swanson CR, Skrinak RT, Hernandez-Con P, Amado DA, Fullard M, Rick J, Siderowf A, Weintraub D, McCluskey L, Trojanowski JQ, Dewey RB Jr, Huang X, Chen-Plotkin AS.

PLoS Med. 2019 Oct 11;16(10):e1002931. doi: 10.1371/journal.pmed.1002931. eCollection 2019 Oct.

2.

Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review.

Mirza S, Yazdani U, Dewey Iii R, Patel N, Dewey RB Jr, Miocinovic S, Chitnis S.

Parkinsons Dis. 2017;2017:3410820. doi: 10.1155/2017/3410820. Epub 2017 Jun 19. Review.

3.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

4.

Blood biomarker for Parkinson disease: peptoids.

Yazdani U, Zaman S, Hynan LS, Brown LS, Dewey RB Jr, Karp D, German DC.

NPJ Parkinsons Dis. 2016;2. pii: 16012. Epub 2016 Jun 23.

5.

Developing a Deep Brain Stimulation Neuromodulation Network for Parkinson Disease, Essential Tremor, and Dystonia: Report of a Quality Improvement Project.

Dewey RB 3rd, O'Suilleabhain PE, Sanghera M, Patel N, Khemani P, Lacritz LH, Chitnis S, Whitworth LA, Dewey RB Jr.

PLoS One. 2016 Oct 6;11(10):e0164154. doi: 10.1371/journal.pone.0164154. eCollection 2016.

6.

The NINDS Parkinson's disease biomarkers program.

Rosenthal LS, Drake D, Alcalay RN, Babcock D, Bowman FD, Chen-Plotkin A, Dawson TM, Dewey RB Jr, German DC, Huang X, Landin B, McAuliffe M, Petyuk VA, Scherzer CR, Hillaire-Clarke CS, Sieber BA, Sutherland M, Tarn C, West A, Vaillancourt D, Zhang J, Gwinn K; PDBP consortium.

Mov Disord. 2016 Jun;31(6):915-23. doi: 10.1002/mds.26438. Epub 2015 Oct 7.

7.

Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.

Brown DS, Bernstein IH, McClintock SM, Munro Cullum C, Dewey RB Jr, Husain M, Lacritz LH.

Int J Geriatr Psychiatry. 2016 Mar;31(3):264-72. doi: 10.1002/gps.4320. Epub 2015 Jul 14.

8.

Deep brain stimulation of the subthalamic nucleus: taking the ouch out of Parkinson disease.

Khemani P, Dewey RB Jr.

JAMA Neurol. 2015 May;72(5):499-500. doi: 10.1001/jamaneurol.2015.36. No abstract available.

PMID:
25799251
9.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

10.

No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.

Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB Jr, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O.

PLoS One. 2014 Dec 8;9(12):e112287. doi: 10.1371/journal.pone.0112287. eCollection 2014.

11.

Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease.

Dewey DC, Miocinovic S, Bernstein I, Khemani P, Dewey RB 3rd, Querry R, Chitnis S, Dewey RB Jr.

J Neurol Sci. 2014 Oct 15;345(1-2):131-8. doi: 10.1016/j.jns.2014.07.026. Epub 2014 Jul 19.

12.

Motor symptoms at onset of Parkinson disease and risk for cognitive impairment and depression.

Dewey RB Jr, Taneja A, McClintock SM, Cullum CM, Dewey RB 3rd, Bernstein I, Husain MM.

Cogn Behav Neurol. 2012 Sep;25(3):115-20. doi: 10.1097/WNN.0b013e31826dfd62.

13.

Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.

Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB Jr, Okun MS, Sullivan KL, Weiner WJ.

Neurology. 2011 Nov 8;77(19):1752-5. doi: 10.1212/WNL.0b013e318236f0fd. Epub 2011 Oct 19. Review.

14.

Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.

Chitnis S, Jaffery M, Dewey RB.

Int J Neurosci. 2012 Jan;122(1):22-5. doi: 10.3109/00207454.2011.617016. Epub 2011 Sep 29.

PMID:
21864207
15.

Pathological gambling in PD: did the devil make me do it?

Dewey RB Jr.

Neurology. 2010 Nov 9;75(19):1668-9. doi: 10.1212/WNL.0b013e3181fc2898. Epub 2010 Oct 6. No abstract available.

PMID:
20926785
16.

Attitudes and performance of third- vs fourth-year neurology clerkship students.

Dewey RB Jr, Agostini M.

Arch Neurol. 2010 May;67(5):548-51. doi: 10.1001/archneurol.2010.64.

PMID:
20457953
17.

Medical management of motor fluctuations.

Dewey RB Jr.

Neurol Clin. 2008 Aug;26(3 Suppl):S15-27, v. doi: 10.1016/j.ncl.2008.05.006. Review.

PMID:
18774440
18.

A stereotactic near-infrared probe for localization during functional neurosurgical procedures: further experience.

Giller CA, Liu H, German DC, Kashyap D, Dewey RB.

J Neurosurg. 2009 Feb;110(2):263-73. doi: 10.3171/2008.8.JNS08728.

PMID:
19012484
19.

Clinical outcome of unilateral stereotactic pallidotomy without microelectrode recording for intractable Parkinson's disease.

Dewey RB Jr, Giller CA, Broline SK, Mendelsohn DB, Lacritz LH, Cullum CM.

Parkinsonism Relat Disord. 2000 Jan;6(1):7-16.

PMID:
18591146
20.

Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists.

Singh A, Kandimala G, Dewey RB Jr, O'Suilleabhain P.

J Clin Neurosci. 2007 Dec;14(12):1178-81. Epub 2007 Aug 27.

PMID:
17720504
21.

Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.

Dewey RB 2nd, Reimold SC, O'Suilleabhain PE.

Arch Neurol. 2007 Mar;64(3):377-80.

PMID:
17353380
22.

Clinical course in Parkinson's disease with elevated homocysteine.

O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R.

Parkinsonism Relat Disord. 2006 Mar;12(2):103-7. Epub 2005 Dec 20.

PMID:
16368256
23.

Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB Jr, Ondo WG, Gronseth GS, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2005 Jun 28;64(12):2008-20. Epub 2005 Jun 22.

PMID:
15972843
24.

10 questions about using apomorphine for Parkinson disease.

Dewey RB Jr.

Neurologist. 2005 May;11(3):190-2. No abstract available.

PMID:
15860144
25.

Autonomic dysfunction in Parkinson's disease.

Dewey RB Jr.

Neurol Clin. 2004 Oct;22(3 Suppl):S127-39. Review. No abstract available.

PMID:
15501361
26.

Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease.

O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R.

Mov Disord. 2004 Dec;19(12):1403-8.

PMID:
15390053
27.

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.

Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr.

Neurology. 2004 Jul 27;63(2):301-4.

PMID:
15277624
28.

Movement disorders after head injury: diagnosis and management.

O'Suilleabhain P, Dewey RB Jr.

J Head Trauma Rehabil. 2004 Jul-Aug;19(4):305-13. Review.

PMID:
15263858
29.
30.

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.

O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R.

Arch Neurol. 2004 Jun;61(6):865-8.

PMID:
15210523
31.

Management of motor complications in Parkinson's disease.

Dewey RB Jr.

Neurology. 2004 Mar 23;62(6 Suppl 4):S3-7. Review.

PMID:
15037664
32.
33.

Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography.

Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB Jr, Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, Kramer PD.

Neurology. 2003 Sep 23;61(6):848-50.

PMID:
14504338
34.

A randomized trial of amantadine in Huntington disease.

O'Suilleabhain P, Dewey RB Jr.

Arch Neurol. 2003 Jul;60(7):996-8.

PMID:
12873857
35.

Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques.

Frohman EM, Kramer PD, Dewey RB, Kramer L, Frohman TC.

Mult Scler. 2003 Jun;9(3):250-5. Review.

PMID:
12814171
36.

Adult polyglucosan body disease associated with lewy bodies and tremor.

Trivedi JR, Wolfe GI, Nations SP, Burns DK, Bryan WW, Dewey RB Jr.

Arch Neurol. 2003 May;60(5):764-6.

PMID:
12756142
37.

A new measure of dysconjugacy in INO: the first-pass amplitude.

Frohman EM, O'Suilleabhain P, Dewey RB Jr, Frohman TC, Kramer PD.

J Neurol Sci. 2003 Jun 15;210(1-2):65-71.

PMID:
12736091
38.
39.

Tremor response to polarity, voltage, pulsewidth and frequency of thalamic stimulation.

O'Suilleabhain PE, Frawley W, Giller C, Dewey RB Jr.

Neurology. 2003 Mar 11;60(5):786-90.

PMID:
12629234
40.

Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease.

O'Suilleabhain PE, Dewey RB Jr.

Arch Neurol. 2002 Jun;59(6):986-9.

PMID:
12056935
41.

Randomized trial comparing primidone initiation schedules for treating essential tremor.

O'Suilleabhain P, Dewey RB Jr.

Mov Disord. 2002 Mar;17(2):382-6.

PMID:
11921128
42.

Proprioception in Parkinson's disease is acutely depressed by dopaminergic medications.

O'Suilleabhain P, Bullard J, Dewey RB.

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):607-10.

43.

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA.

Arch Neurol. 2001 Sep;58(9):1385-92.

PMID:
11559309
44.

Validation for tremor quantification of an electromagnetic tracking device.

O'Suilleabhain PE, Dewey RB Jr.

Mov Disord. 2001 Mar;16(2):265-71.

PMID:
11295779
45.

Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease.

Dewey RB Jr, O'Suilleabhain PE.

Neurology. 2000 Dec 12;55(11):1753-4. No abstract available.

PMID:
11113242
46.

Vertigo in MS: utility of positional and particle repositioning maneuvers.

Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC.

Neurology. 2000 Nov 28;55(10):1566-9.

PMID:
11094117
47.

Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease.

Lemack GE, Dewey RB Jr, Roehrborn CG, O'Suilleabhain PE, Zimmern PE.

Urology. 2000 Aug 1;56(2):250-4.

PMID:
10925088
48.

Neuropsychological outcome following unilateral stereotactic pallidotomy in intractable Parkinson's disease.

Lacritz LH, Cullum CM, Frol AB, Dewey RB Jr, Giller CA.

Brain Cogn. 2000 Apr;42(3):364-78. Review.

PMID:
10753485
49.

Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure.

Dewey RB Jr, Rao SD, Holmburg SL, Victor RG.

Eur J Neurol. 1998 Nov;5(6):593-599.

PMID:
10210895
50.

Long-term follow-up of levodopa responsiveness in generalized dystonia.

Dewey RB Jr, Muenter MD, Kishore A, Snow BJ.

Arch Neurol. 1998 Oct;55(10):1320-3.

PMID:
9779659

Supplemental Content

Loading ...
Support Center